MedMen’s ends blockbuster deal adding to cannabis stock woes

[ad_1]

On Tuesday, MedMen Enterprises Inc., which sells legal cannabis in California and 11 other states, backed out of a blockbuster deal to purchase PharmaCann, a Chicago-primarily based marijuana organization with operations in eight states.

In its announcement, Los Angeles-primarily based MedMen cited the steep pullback in U.S. and Canadian cannabis stocks this year. It noted the Horizons Marijuana Life Sciences Index, a Canadian exchange-traded fund that tracks cannabis stocks, is down 47% considering that March.

“The underperformance has produced it increasingly much more important to allocate capital effectively, offered the existing sector headwinds,” MedMen mentioned in a news release.

The deal was announced in December and was noticed as a forerunner of a wave of marijuana sector mergers and acquisitions promising significant returns for investors.

Billions poured into marijuana stocks final year as investors got on board with the significant, multistate operators with the funds to obtain expensive licenses in the 11 states exactly where it is legal to sell cannabis items.

A flurry of bargains in late 2018 and early this year continued to entice investors. But hopes of mergers having rapid regulatory approval quickly faded as the U.S. Justice Division started to evaluation the bargains for possible antitrust violations. That evaluation method has but to be completed, although some analysts anticipate the bargains could commence closing as early as this month.

“There’s been a delay in M&ampA activity and that is prompted investors to step away from the sector till they know M&ampA activity is going to choose up once more,” mentioned Bobby Burleson, an analyst with Canaccord Genuity. “That’s type of dampened enthusiasm for the sector, mainly because that was 1 exit path that looked like it was closed temporarily.”

Investors have had no shortage of motives lately to sour on marijuana stocks, beyond the delay in deal approvals.

Vaping-connected deaths and illnesses have contributed to the slide in some cannabis stocks. States like Massachusetts and Montana have also temporarily banned sales of flavored electronic cigarettes and vaping items in a bid to cut down underage use.

Vaping of marijuana items in states exactly where it is legal for adults account for more than a quarter of income for the sector and, in some circumstances, 30% or much more of sales, Burleson mentioned.

“People are waiting to see irrespective of whether or not there’s been a unfavorable effect more than all on sector income,” he mentioned.

Also weighing on marijuana stocks is a improve in stock industry volatility brought about by a slowing U.S. economy and uncertainty more than the trade war involving the U.S. and China.

Nevertheless, cannabis stocks are a significant loser so far this year, relative to the broader industry.

Take into account, the ETFMG Option Harvest exchange traded fund, which focuses on cannabis stocks: It is down 19.six% this year and off practically 50% from a year ago. And shares in some of the most significant marijuana organizations, like Tilary, Canopy Development, and Aurora Cannabis are down much more than 50% from a year ago.

Several significant organizations that have invested in cannabis enterprises are also down much more than 10% from a year ago, like Altria Group, AbbVie, Molson Coors Brewing and Constellation Brands.

By comparison, the benchmark S&ampP 500 index is up 15.four% this year and hovering slightly above exactly where it stood 12 months ago.

A much less welcoming stock industry can limit a company’s capacity to raise capital by issuing stock. MedMen noted that a huge portion of PharmaCann’s cultivation and manufacturing assets needs “significant capital expenditures.”

“There’s been a lot much less capacity to go to the markets and raise capital, so investors are scrutinizing the balance sheets of public organizations to see who’s ideal positioned to climate the dry spell in capital markets,” Burleson mentioned.

Now that it has backed out of its bid for PharmaCann, MedMen mentioned it intends to concentrate on developing its retail brand and on the internet business enterprise. In exchange for forgiving some debt, the organization is taking specific cannabis licenses and other assets in Illinois and Virginia from PharmaCann.

“Looking at the PharmaCann portfolio currently, Illinois has emerged as the most eye-catching chance for our longer-term, strategic development strategy,” mentioned Adam Bierman, MedMen co-founder and CEO.

Supply: AP

[ad_2]

Latest posts